Safety and efficacy of antiplatelet therapy in patients with intermediate coronary artery stenosis and deferred revascularization

• Published in: Revista española de cardiología (English ed.) 2024-11
• Main Authors: Hong, David, Lee, Seung Hun, Heo, Jihye, Shin, Doosup, Cho, Juhee, Guallar, Eliseo, Joh, Hyun Sung, Kim, Hyun Kuk, Ha, Junho, Choi, Ki Hong, Park, Taek Kyu, Yang, Jeong Hoon, Song, Young Bin, Hahn, Joo-Yong, Choi, Seung-Hyuk, Gwon, Hyeon-Cheol, Kang, Danbee, Lee, Joo Myung
• Format: Article
• Language: English
• Subjects: Antiplatelet therapy; Estenosis coronaria intermedia; Fractional flow reserve; Intermediate coronary artery stenosis; Prognosis; Pronóstico; Reserva fraccional de flujo; Tratamiento antiplaquetario
• ISSN: 1885-5857; 1885-5857
• DOI: 10.1016/j.rec.2024.11.001

This study investigated the safety and efficacy of antiplatelet therapy in patients with intermediate coronary artery stenosis who underwent deferred revascularization due to their fractional flow reserve (FFR). A nationwide cohort study was conducted using the Korean National Health Insurance Service database. A total of 4657 patients with intermediate coronary artery stenosis who underwent deferred revascularization due to their FFR were identified from 2013 to 2020. FFR was indicated in patients with no prior evidence of myocardial ischemia and intermediate coronary artery stenosis (50%-70%) as determined by quantitative coronary angiography. Patients were classified according to whether antiplatelet therapy was initiated after the index procedure. The primary efficacy outcome was major adverse cardiac and cerebrovascular events (MACCE), a composite of all-cause death, myocardial infarction, unplanned revascularization, and stroke, during a 5-year follow-up period. The primary safety outcome was any gastrointestinal bleeding. After propensity score matching, there were 1634 patients in the antiplatelet therapy group and 1634 in the nonantiplatelet therapy group. The risk of MACCE was similar between the 2 groups (24.8% vs 24.7%; adjusted HR, 0.97; 95%CI, 0.84-1.13; P=0.745). The risk of gastrointestinal bleeding was higher in the antiplatelet therapy group than in the nonantiplatelet therapy group (2.2% vs 1.2%; aHR, 2.07; 95%CI, 1.08-4.00). These results were similar in subgroup analyses. In patients with intermediate coronary artery stenosis who underwent deferred revascularization due to their FFR, antiplatelet therapy may increase the risk of gastrointestinal bleeding without reducing the risk of future ischemic events. Este estudio investigó la seguridad y eficacia del tratamiento antiplaquetario en pacientes con estenosis intermedia de arterias coronarias en los que se aplazó la revascularización en función de la reserva fraccional de flujo (RFF). Estudio de cohortes realizado con datos del Servicio Nacional de Seguros de Salud de Corea. Entre 2013 y 2020, se identificaron un total de 4.657 pacientes con estenosis intermedia de arterias coronarias en los que se aplazó la revascularización en función de la RFF. La RFF se indicó para pacientes sin evidencia previa de isquemia miocárdica y estenosis intermedia de arterias coronarias (50-70%) en angiografía coronaria cuantitativa. Los pacientes se clasificaron según el inicio o no del tratamiento anti